Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share Price (SCLP)

Share Price Information for Scancell Holdings (SCLP)

Share Price is delayed by 15 minutes
Get Live Data
22.50    0.10 (0.44%)
Bid:
22.00
Ask:
23.00
Spread: 1.00 (4.545%)
Market Cap: £234.54m
SCLP Live PriceLast checked at - London Stock Exchange

Intraday Scancell Holdings Share Chart

Scancell Holdings Share Price
Price 22.50 Open 22.75
Bid 22.00 High 22.60
Ask 23.00 Low 22.60
Change 0.10 (0.44%) Close 22.50
Volume 708,467
Currency GBX
Issue Country GB
Shares in Issue 1.04b
Market Cap £234.54m
PE Ratio -17.93651
EPS -1.26
Year High 27.80
Year High Date 19-May-2026
Year Low 7.90
Year Low Date 11-Sep-2025
Dividend 0.00
Yield 0.00%
# Trades 65
Vol. Sold 431,691
Sold Value £96.14k
Vol. Bought 231,776
Bought Value £52.37k
Market Size 30,000
What if I invested £1,000 in Scancell Holdings?
£ 1,363.64 (+36.36%)
1 month ago
£ 1,750.97 (+75.10%)
3 months ago
£ 2,261.31 (+126.13%)
6 months ago
£ 2,142.86 (+114.29%)
1 year ago
Add SCLP to WatchlistAdd SCLP to Watchlist

Compare Broker Offers

Selected partners may offer promotions for new customers. We may earn a referral fee if you open an account

Great for:
Active Traders
View Offer
Capital at risk
Great for:
Copy Trading
View Offer
Other fees apply.
Capital at risk.
Great for:
ISAs & SIPPs
View Offer
Capital at risk
Great for:
Beginner Friendly
View Offer
Capital at risk
Scancell Holdings Plc Ord 0.1p

Scancell Holdings is listed in the FTSE AIM All-Share index.

Scancell Holdings is listed in the Medicine and Biotech sector.

Scancell Holdings Plc Ord 0.1p is listed on the London Stock Exchange trading with ticker code SCLP.L. It has a market capitalisation of £234.54m, with approximately 1.04b shares in issue. Over the last year, Scancell Holdings share price has been traded in a range of 19.90, hitting a high of 27.80, and a low of 7.90.

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.

Some Videos You Might Like

What's Hot 8th April 2026


 

What's Hot end of April


Recent Share Trades for Scancell Holdings (SCLP)

Date Time Trade Prc Volume Buy/Sell Bid Ask Value  
05-Jun-2616:26:2822.154,951Sell*22.0023.001,097O Ordinary
05-Jun-2616:16:4322.007Sell*22.0023.001.54O Ordinary
Trade was executed as an SI
05-Jun-2616:16:4323.0050Buy*22.0023.0011.50O Ordinary
Trade was executed as an SI
05-Jun-2616:16:4323.0050Buy*22.0023.0011.50O Ordinary
Trade was executed as an SI
05-Jun-2616:16:4322.008,181Sell*22.0023.001,800O Ordinary
Trade was executed as an SI
05-Jun-2616:16:4322.0060Sell*22.0023.0013.20O Ordinary
Trade was executed as an SI
05-Jun-2616:16:4323.0020Buy*22.0023.004.60O Ordinary
Trade was executed as an SI
05-Jun-2616:15:5722.5015,000Unknown*22.0023.003,375O Ordinary
05-Jun-2616:13:3622.152,161Sell*22.0023.00478.66O Ordinary
05-Jun-2616:12:4422.001,953Sell*22.0023.00429.66O Ordinary

Directors Deals for Scancell Holdings (SCLP)

Announced Traded Action Notifier Price Currency Amount Holding
16-Sep-2512-Sep-25BuyMartin Diggle held the position of Non-Executive Director at the time of this trade.Martin Diggle8.86GBX3,150,000140,387,037
08-Aug-2507-Aug-25BuyMartin Diggle held the position of Non-Executive Director at the time of this trade.Martin Diggle10.85GBX102,236140,387,037
04-Aug-2501-Aug-25BuyMartin Diggle held the position of Non-Executive Director at the time of this trade.Martin Diggle10.00GBX4,400,000140,284,801
04-Aug-2530-Jul-25BuyMartin Diggle held the position of Non-Executive Director at the time of this trade.Martin Diggle10.00GBX5,000,000140,284,801
21-May-2520-May-25BuyMartin Diggle held the position of Non-Executive Director at the time of this trade.Martin Diggle9.00GBX44,944130,884,801
Scancell Holdings

Scancell is a clinical stage immunotherapy biotech developing treatments for significant unmet needs in cancer.

Scancell Holdings Home Page